Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 1/2 2Phase 2/3 1

Status

Completed 5Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 6OTHER 2

Study Type

Interventional 8

Sponsor

Cancer Type

Tumor-Agnostic 4Genitourinary 3

Conditions

Prostatic Neoplasms 52Neoplasm Metastasis 11Neoplasms 8Recurrence 7Prostate Cancer Metastatic 6Breast Neoplasms 5Carcinoma, Transitional Cell 4Stomach Neoplasms 3Neoplastic Cells, Circulating 3Metastatic Castration-resistant Prostate Cancer 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms, Castration-Resistant 2Ovarian Neoplasms 2Glioblastoma 2Carcinoma, Squamous Cell 2Thrombocytosis 1Testicular Neoplasms 1Solid Cancer 1Small Cell Lung Carcinoma 1Prostate Cancer, Hereditary, 7 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Myeloproliferative Disorders 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Neoplasms × cabazitaxel × Clear all
NCT06691984 2026-05-15

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Amgen

Phase 3 Active not recruiting
707 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT02202772 2025-02-24

CGC

Columbia University

Phase 1/2 Active not recruiting
51 enrolled

Carcinoma, Neoplasms, Recurrence

NCT01668459 2018-12-04

CabB1

University Hospital Birmingham NHS Foundation Trust

Phase 2/3 Completed
20 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT01447225 2016-09-14

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

Merrimack Pharmaceuticals

Phase 1 Completed
43 enrolled 21 charts
Tumor-Agnostic

Neoplasms

NCT01140607 2015-07-21

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

Sanofi

Phase 1 Completed
56 enrolled
Tumor-Agnostic

Neoplasms

NCT01001221 2013-09-11

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

Sanofi

Phase 1/2 Terminated
19 enrolled 55 charts
Tumor-Agnostic

Neoplasms

NCT01087021 2011-12-16

QT-Cab

Sanofi

Phase 1 Completed
45 enrolled
Tumor-Agnostic

Neoplasms

NCT00417079 2011-03-10

TROPIC

Sanofi

Phase 3 Completed
755 enrolled 19 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡